biotech

Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Gritstone pushed higher on Tuesday after the company reported that it was advancing the development of a second-generation vaccine against SARS-CoV-2.
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Arcturus Therapeutics shares took a tumble on Tuesday after the company announced update on its COVID-19 vaccine candidate.
Aprea Therapeutics stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatment for...
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
These four sizzling biotech stocks trading under the $10 level could provide investors with some solid upside potential. They are all Buy rated at Goldman Sachs, one of the top firms on Wall Street.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.